Tag: Zhu Ke
Cancer drug firm Adlai Nortye raises USD97.5m in Nasdaq IPO
O’Melveny, Han Kun Law Offices, Maples Group, Latham & Watkins and Zhong Lun Law Firm advised on cancer drug developer Adlai Nortye’s Nasdaq debut
Fourth Paradigm clinches HKD1.02bn IPO on fourth endeavour
China’s AI unicorn Fourth Paradigm, after three previous attempts, has successfully listed on the HKEX raising HKD1.02 billion (USD130 million)
Luzhu Biotechnology launches HKD341m IPO via chapter 18A
Luzhu Biotechnology debuted on the HKEX through chapter 18A, the first biotech company without any revenue or profits to be listed this year, raising USD43.45 million
O’Melveny acts on Acotec Scientific’s partial offering
O’Melveny advised China’s medical technology company, Acotec Scientific Holdings, on the voluntary partial offer for a majority stake of up to 65% by US-listed Boston Scientific Group
LATEST ON VANTAGE ASIA
MOST READ ON VANTAGE ASIA
Data Privacy Guide
Understanding India's new data protection regime
